Overview

LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The phase I study will evaluate the safety, efficacy and pharmacokinetics of LBH589B in adult patients with advanced solid tumors or Cutaneous T-cell lymphoma
Phase:
Phase 1
Details
Lead Sponsor:
Novartis
Treatments:
Panobinostat